Get the Stockscreener App
1.01
3.81%
-0.04
After Hours:
1.02
0.01
+0.99%
Adc Therapeutics Sa stock is traded at $1.01, with a volume of 1.34M.
It is down -3.81% in the last 24 hours and down -17.89% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$1.05
Open:
$1.02
24h Volume:
1.34M
Relative Volume:
0.78
Market Cap:
$128.46M
Revenue:
$79.18M
Net Income/Loss:
$-136.99M
P/E Ratio:
-0.9576
EPS:
-1.0547
Net Cash Flow:
$-120.11M
1W Performance:
-10.62%
1M Performance:
-17.89%
6M Performance:
-74.69%
1Y Performance:
-68.34%
1-Day Range:
$1.00
$1.04
1-Week Range:
$0.9393
$1.23
52-Week Range:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Compare ADCT vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.01 | 156.45M | 79.18M | -136.99M | -120.11M | -1.0547 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance
ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180 - TradingKey
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance
ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - marketbeat.com
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com
ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com
ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - quiverquant.com
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - GuruFocus
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ADC Therapeutics SA (ADCT) Stock News Today - TradingKey
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - Morningstar
ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday - marketbeat.com
BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics SA (ADCT) Income Statement - TradingKey
ADCT|ADC Therapeutics SA|Price:1.130|Chg%:+0.005 - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADCT|ADC Therapeutics SA|Price:1.139|Chg%:-0.000 - TradingKey
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics SA (ADCT) Cash Flow - TradingKey
ADC Therapeutics SA (ADCT) Balance Sheet - TradingKey
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review
ADC Therapeutics (ADCT) Holds Steady at $1.35 as Key Support and Resistance Levels NarrowPairs Trade - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review
ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - Moomoo
Biocytogen and Whitehawk partner to develop ADCs - Pharmaceutical Technology
The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment - ad-hoc-news.de
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):